Abstract
Stroke treatment using cells rather than drugs is a somewhat new experimental approach that has moved from the bench to clinical trials over the past 10 years. Among the different types of cell-based therapies, autologous mononuclear cells from the patient's own bone marrow represent a promising approach, supported by extensive data from animal studies.1 Mononuclear cells release biological factors that might modify the post-ischaemic inflammatory response and augment brain repair mechanisms such as neurogenesis and angiogenesis.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call